Mercy Medical Center Expands Access to Cutting-edge Cancer Trials in Springfield
SPRINGFIELD — Mercy Medical Center, through its affiliation with the US Oncology Network, is now conducting community-based clinical trials by collaborating with Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials.
Since its inception, SCRI has conducted more than 850 first-in-human trials and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. SCRI at Mercy Medical Center will provide access to increased research options for patients facing cancer and opportunities to enroll in trials evaluating cutting-edge therapies.
“We are in a transformative moment in community-based cancer care. Therapeutic options have never been more promising,” said Dr. Philip Glynn, director of Medical Oncology at Mercy Medical Center. “As we move beyond the limitations of conventional chemotherapy toward more tolerable and effective personalized treatment, collaboration with research institutions will be key. For Mercy Medical Center and the Sister Caritas Cancer Center, our partnership with the US Oncology Network and Sarah Cannon Research Institute is foundational to our growth and commitment to excellence in care. We are eager for the opportunity to bring Sarah Cannon Research Institute’s clinical trials to our community.”
The collaboration with SCRI offers several advantages for cancer patients, including greater treatment options — eligible patients will have access to a wider range of clinical trials, offering options based on their individualized treatment plan — and access to cutting-edge therapies, as eligible patients will have the opportunity to participate in trials evaluating the latest advancements in cancer research.
“By collaborating with the experts at Mercy Medical Center, we can make a significant impact throughout Western Massachusetts for people living with cancer by expanding access to novel, cutting-edge treatment options,” said Dee Anna Smith, CEO of SCRI. “Together, we are working to advance oncology care and clinical research to improve access to novel therapies and enable best-in-class, community-based care.”